文献速递肝病消化道肿瘤与早癌

肝组织IFIT3可预测肝细胞癌患者对干扰素-α治疗的应答

Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2017-05-26

研究在肝细胞癌组织中筛选干扰素刺激基因,发现IFIT1、IFIT2、IFIT3、IFIT5表达降低,并在两项独立的干扰素-α治疗随机对照临床试验中分析IFIT家族成员表达与患者应答的关系。结果显示肝癌组织中IFIT3高表达(而非其他IFIT成员)预示对干扰素-α治疗应答更好;机制上IFIT3通过结合STAT1与STAT2增强IFN-α效应信号。

要点

  • 肝癌组织中IFIT1、IFIT2、IFIT3、IFIT5表达降低。
  • 肝癌组织IFIT3高表达预示对干扰素-α治疗应答更好,其他IFIT成员无此预测作用。
  • IFIT3通过结合STAT1和STAT2增强IFN-α效应信号,促进其抗肿瘤作用。

核心结论

  • 肝癌组织中IFIT3高表达可预测肝细胞癌患者对干扰素-α治疗应答更好;IFIT3通过增强IFN-α效应信号促进IFN-α效应应答和治疗效果。

研究设计与样本

  • 在肝细胞癌组织中筛选干扰素刺激基因表达,并在两项独立的肝细胞癌患者干扰素-α治疗随机对照临床试验中分析IFIT家族成员表达与治疗应答的关系;机制研究包括体外和体内实验。

主要发现

  • 肝癌组织中IFIT1、IFIT2、IFIT3、IFIT5表达降低。
  • 两项独立随机对照干扰素-α治疗临床试验中,肝癌组织IFIT3高表达预示对干扰素-α治疗应答更好,其他IFIT成员无此预测作用。
  • IFIT3在体外和体内增强IFN-α的抗肿瘤作用;IFN-α处理时IFIT3可结合STAT1和STAT2,增强STAT1-STAT2异二聚化及核转位,从而促进IFN-α效应信号。

临床怎么用

  • 作者认为肝癌组织IFIT3高表达可能是预测肝细胞癌患者对干扰素-α治疗应答的有用指标。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Adjuvant interferon-α (IFN-α) therapy is used to control certain types of cancer in clinics. For hepatocellular carcinoma (HCC), IFN-α therapy is effective in only a subgroup of patients; therefore, identifying biomarkers to predict the response to IFN-α therapy is of high significance and clinical utility. As the induced IFN-stimulated gene expression following IFN-α treatment plays pivotal roles in IFN-α effects, we screened IFN-stimulated gene expression in HCC tissues and found that several IFN-stimulated genes were significantly decreased in HCC. Interestingly, expression of IFN-induced protein with tetratricopeptide repeats (IFIT) family members, including IFIT1, IFIT2, IFIT3, and IFIT5, was decreased in HCC tissues. We further analyzed the expression of IFIT family members in HCC and their roles in patients' responses to IFN-α therapy in two independent randomized controlled IFN-α therapy clinical trials of HCC patients. We found that higher expression of IFIT3, but not other IFITs, in HCC tissues predicts better response to IFN-α therapy, suggesting that IFIT3 may be a useful predictor of the response to IFN-α therapy in HCC patients. Mechanistically, IFIT3 enhanced the antitumor effects of IFN-α by promoting IFN-α effector responses both in vitro and in vivo. IFIT3 could bind signal transducer and activator of transcription 1 (STAT1) and STAT2 to enhance STAT1-STAT2 heterodimerization and nuclear translocation upon IFN-α treatment, thus promoting IFN-α effector signaling. CONCLUSION: Higher IFIT3 expression in HCC tissues predicts better response to IFN-α therapy in HCC patients; IFIT3 promotes IFN-α effector responses and therapeutic effects by strengthening IFN-α effector signaling in HCC. (Hepatology 2017;66:152-166).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Yang Y, Zhou Y, Hou J, et al. Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma. Hepatology. 2017. PMID: 28295457. doi:10.1002/hep.29156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。